Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ly Tu

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2020
Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary HypertensionJennifer Bordenave, Ly Tu, Nihel Berrebeh, et al.
Journal of Medicinal Chemistry|March 13, 2018
Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary HypertensionMorane Le Hiress, Bernardin Akagah, Guillaume Bernadat, et al.
Pulmonary Circulation|December 6, 2011
Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphismThibaud Damy, Pierre-François Lesault, Soulef Guendouz, et al.
The European Respiratory Journal|February 25, 2012
Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertensionAlice Huertas, Ly Tu, Natalia Gambaryan, et al.
Cardiovascular Research|July 13, 2020
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertensionMarie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, et al.
Annals of the Rheumatic Diseases|August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertensionJerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Metabolites|November 25, 2021
Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?Thomas Duflot, Ly Tu, Matthieu Leuillier, et al.
American Journal of Respiratory and Critical Care Medicine|July 24, 2015
Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 ComplexMorane Le Hiress, Ly Tu, Nicolas Ricard, et al.
Chest|February 3, 2016
Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial HypertensionAlice Huertas, Carole Phan, Jennifer Bordenave, et al.
Chest|April 8, 2009
Role for interleukin-6 in COPD-related pulmonary hypertensionAri Chaouat, Laurent Savale, Christos Chouaid, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2020
Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary HypertensionJennifer Bordenave, Ly Tu, Nihel Berrebeh, et al.
Journal of Medicinal Chemistry|March 13, 2018
Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary HypertensionMorane Le Hiress, Bernardin Akagah, Guillaume Bernadat, et al.
Pulmonary Circulation|December 6, 2011
Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphismThibaud Damy, Pierre-François Lesault, Soulef Guendouz, et al.
The European Respiratory Journal|February 25, 2012
Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertensionAlice Huertas, Ly Tu, Natalia Gambaryan, et al.
Cardiovascular Research|July 13, 2020
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertensionMarie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, et al.
Annals of the Rheumatic Diseases|August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertensionJerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Metabolites|November 25, 2021
Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?Thomas Duflot, Ly Tu, Matthieu Leuillier, et al.
American Journal of Respiratory and Critical Care Medicine|July 24, 2015
Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 ComplexMorane Le Hiress, Ly Tu, Nicolas Ricard, et al.
Chest|February 3, 2016
Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial HypertensionAlice Huertas, Carole Phan, Jennifer Bordenave, et al.
Chest|April 8, 2009
Role for interleukin-6 in COPD-related pulmonary hypertensionAri Chaouat, Laurent Savale, Christos Chouaid, et al.
Pageof 9